Michael Bauer explains at PharmaBoardroom why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in cancer research, the ways in which the firm’s funding strategy has evolved, and how its future growth trajectory might look.
To read the Interview please click here.
Previous news
